4th Cell Therapy Potency Assay Summit
2025-03-11 - 2025-03-13 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
In the current cell therapy landscape, where funding is tight and clinical development a priority, developing robust potency assays is critical to avoid costly delays. Introducing the 4th Cell Therapy Potency Assay Summit, uniting AD, QC and regulatory experts, this summit works to design potency assays that not only conform to changing guidelines but also streamline patient access to the next generation of cell therapies.
Join leading organizations like Arsenal Biosciences, BlueRock Therapeutics, the NIST and Vertex Pharmaceuticals, as they share development strategies and the latest technologies needed to streamline your assay development workflows. You won’t want to miss out!
To know more visit: https://ter.li/inqax5

6th Supply Chain & Logistics for Cell & Gene Therapies Summit
2025-03-11 - 2025-03-13 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The 6th Supply Chain & Logistics for Cell & Gene Therapies Summit is the ultimate practical guide for designing scalable, traceable, and resilient global supply chains to support the growing number of complex cell and gene therapies. It is an industry wide challenge and vital part of development, to ensure safe and timely delivery to patients. This relies on robust global supply chains.
The 2025 summit will provide a comprehensive deep dive into end-to-end global supply chains for cell and gene therapies, covering autologous, allogeneic, in vivo, and ex vivo programs. This is the industry’s premier platform to hear from more than 20 leading voices spanning clinical and commercial drug developers, trusted service providers, and clinical experts who will be sharing solution-driven case studies. These will focus on key areas such as defining robust processes, securing reliable material supplies, implementing digital solutions, and ensuring seamless traceability of chain of identity and custody throughout the cold chain.
Our 90+ attendees will gain invaluable and actionable insights on how to become commercial-ready, expand globally, and enhance cross-functional collaboration. The summit will unite professionals from Supply Chain, Logistics, Sourcing, Quality, and Operations sectors, who will share best practices in supply planning, manufacturing, packaging, labeling, and delivery. Together, they will brainstorm practical solutions for an integrated approach that strengthens value chains.
For those planning or executing a scaled, integrated CGT supply chain, this summit provides a unique opportunity to innovate and address the logistical and operational challenges currently facing the industry. As the industry’s premier networking and knowledge-based event dedicated to optimizing cell and gene therapy supply chains, you don’t miss out on this opportunity to network, learn, and collaborate with experts in the field.
To learn more about who will be attending including those from Novartis, Beam Therapeutics, Astellas Gene Therapies, and more – download the event guide now.
To know more visit: https://ter.li/yjybt6

The 5th Operationalize: Expanded Access Programs Summit
2025-03-18 - 2025-03-20 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. However, challenges persist, especially when navigating the complex regulatory landscape of global programs. From country-specific regulations to post-trial access, managing global supply chains, importation, licensing, and labeling standards remains a critical focus for ensuring patients worldwide receive the treatments they need.
Join over 120 thought leaders from Access, Medical Affairs, Clinical Operations, and Clinical Supply for an unparalleled opportunity to network, exchange insights, and explore innovative strategies for overcoming the regulatory and operational hurdles that complicate global access to life-saving therapies.
At this year’s summit, you’ll gain actionable insights on successfully planning and executing Post-Trial Access Programs, navigating the regulatory landscapes of the US, LATAM, Europe, and South & East Asia, and developing compliant, effective global access strategies. You’ll also explore best practices for creating exit plans and transition strategies that address hurdles in reimbursement, off-request processes, and country-specific regulations—plus so much more!
To know more visit: https://ter.li/org1vd

5th Wet AMD Diabetic Eye Disease Drug Summit
2025-03-18 - 2025-03-20 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
With Merck’s acquisition of EyeBio for $1.3 Billion, Roche’s Vabysmo launch success and multiple other phase II and III trials in DME, DR, RVO, and Wet AMD, there is plenty to discuss in the retinal vascular drug space as drug developers seek to new alternatives to anti-VEGF, explore biosimilars, and target retinal fibrosis and more to find truly transformative drugs for patients.

The 2025 Wet AMD & Diabetic Eye Disease Summit is set to be an essential meeting for industry leaders, research innovators, and clinical experts dedicated to transforming the landscape of retinal vascular disease treatments.
What’s New for the 2025 Wet AMD & Diabetic Eye Disease Drug Summit?

New Strategies for Retinal Vascular Drug Clinical Trials: Delve into advanced strategies for designing clinical trials in Wet AMD and diabetic eye disease, focusing on patient-specific factors and adaptive trial models with insights from Bayer and Aviceda Therapeutics
Emerging Biomarker Approaches Wet AMD, DR. DME & RVO: Explore the critical role of biomarkers and clinical endpoints in developing therapies for neovascular retinal disorders, featuring discussions from Opus Genetics and Ocugen
Innovative Oral Anti-Inflammatory Treatments for Diabetic Eye Disease: Discover how InflammX Therapeutics is addressing the unmet need in DR and DME patients non-responsive to anti-VEGF therapy with their once-daily oral small molecule
Advancements in Retinal Drug Delivery: Discover the benefits of suprachoroidal TKI delivery for Wet AMD with Clearside Biomedical, and hear from Sanofi about incorporating drug delivery devices to improve physician efficiency and patient compliance
Breakthroughs in Wet AMD Gene Therapy: Learn about emerging gene therapies for Wet AMD, focusing on innovative approaches and potential impact on patient care with HuidaGene Therapeutics Doheny Eye Centers

Join 50+ biopharma experts from clinical, medical, regulatory. value and access departments from Bayer, Sanofi, EyePoint, Ocular Therapeutix, Clearside Biomedical, RevOpsis, Opus Genetics, and HuidaGene Therapeutics as they accelerate towards releasing longer-lasting, non-invasive and more effective drugs for retinal disease patients.
To know more visit: https://ter.li/sew767

4th Novel Conjugate Summit
2025-03-25 - 2025-03-27 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The field of conjugatable drugs is advancing at a rapid pace, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals, which paves the way towards a new generation of more targeted, safer and efficacious novel conjugated drugs.
The 4th Novel Conjugates Summit is the only event offering comprehensive insights into the latest innovations in bioconjugates. From antibody-degrader conjugates to bispecific ADCs and peptide drug conjugates, join us to delve into each of their value propositions and navigate crucial considerations like target selection, PK/PD profiles, and translation into the clinic.
Connect with 100+ experts from big pharma, cutting-edge biotechs and conjugation and manufacturing providers, all sharing crucial insights on striking success with new formats and payloads.
Now is the time to expand your conjugate design toolkit to pursue emerging cancer targets and stay ahead in the race to deliver safer, more targeted therapies beyond traditional ADCs Join us to explore the most promising new targeting vectors and payloads that are set to revolutionize the landscape of conjugated drugs in 2025!

8th Gene Therapy Development Summit
2025-03-25 - 2025-03-27 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining momentum and broadening scope beyond rare diseases.
Returning to Boston in March, the 8th Gene Therapy Development Summit, formerly known as the Gene Therapy for Rare Disorders Summit, will unite 200+ gene therapy experts to tackle the field’s biggest challenges of achieving genuine scalability and accessibility to meet growing patient demand.
For the first time, this industry-defining meeting will reflect the field’s growing focus on developing therapies for common diseases, whilst addressing existing hurdles in rare and ultra-rare disorders. This is your unparalleled opportunity to delve into:

The latest global regulatory requirements
Optimizing routes for CNS
Ocular and inner ear disorders
Innovations in capsid engineering and dosing strategies
Increasing volumetric productivity to reduce CoGs

VIEW THE FULL EVENT GUIDE
Secure your place here or get in touch with the team – info@hansonwade.com

2nd Biophysics for Drug Discovery Summit
2025-03-25 - 2025-03-27 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
In today’s complex drug development landscape, leveraging biophysical tools to unravel the molecular and target engagement intricacies of drug candidates is more critical than ever for successfully advancing molecules through the drug development pipeline. The 2nd Biophysics for Drug Discovery Summit is your exclusive opportunity to unite and network with your biophysics and drug discovery peers and delve into the application of biophysical techniques including SPR, NMR, Thermal shift assays, mass spec, and the emerging technologies, across modalities and targets to inform efficient drug discovery.

The Biophysics for Drug Discovery Summit will delve into the latest in strategy and application of biophysical techniques across novel targets and modalities, from AI-driven drug discovery to fragment-based drug discovery, and in-cell biophysics to single-particle tracking. By understanding the intricate molecular mechanisms and improving hit selection and target identification, we can accelerate the discovery of innovative therapies and improve the effectiveness and efficiency of drug development.
Unlock the future of therapeutics through biophysics and keep up to date as field evolves into new technologies and applications, this meeting will provide you with thought-provoking insights on biophysics applications to take away to your wider drug discovery teams. Join the Biophysics for Drug Discovery Summit in March 2025 and build meaningful connections with 70+ biophysicists and drug discovery experts and move the field forward with unique insights and deep-dive conversations.
To know more visit: https://ter.li/8u0s3n

2nd EHS for Biopharma Summit East
2025-03-25 - 2025-03-27 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
As the biopharma industry evolves with rapid advancements in drug development, manufacturing, and research, EHS leaders are tasked with safeguarding employee health, maintaining a culture of safety, and addressing environmental concerns. Navigating these challenges while meeting sustainability goals and mitigating risks has become essential for operational success. EHS professionals must continuously adapt to this dynamic landscape to protect their most valuable asset: their workforce.
The 2nd EHS for Biopharma East Summit is an essential event for EHS professionals working in the biopharma industry, focused on overcoming the sector’s unique regulatory and operational challenges. With over 100+ attendees, this summit will provide valuable insights on navigating evolving regulations, optimizing safety protocols, and enhancing environmental stewardship. Whether your goal is to strengthen safety culture, reduce incidents, or achieve sustainability targets, the summit offers the tools, knowledge, and networking opportunities necessary to elevate EHS practices.
What can you expect? – Your Definitive Guide to EHS for Biopharma

Discover actionable strategies for managing global EHS challenges with insights from Astellas, MilliporeSigma, and Elanco
Enhance safety culture in laboratory and manufacturing settings with guidance from AstraZeneca, Texcell, and Cytovance
Learn best practices for embedding EHS programs within the workforce, fostering leadership buy-in, employee engagement, and promoting psychological well-being to minimize burnout
Explore the latest technologies driving EHS excellence with expertise from AstraZeneca and Sanofi
Connect with industry peers to network and benchmark best practices.
Earn continuing education credits from BCSP, ABSA, and CIH

Created for EHS professionals spanning EHS directors, EHS managers and EHS technical experts focused on workplace safety, environmental compliance, and operational excellence.
Join us this March
Find out more here
Register your place

7th Treg-Directed Therapies Summit
2025-03-25 - 2025-03-27 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Over the past year, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca, and Parvus and AbbVie, creating a surge of innovation and spotlighting Treg cell therapies and modulators as the next frontier in autoimmune and inflammatory disease treatments. Tregs hold the potential to revolutionize care for conditions that have long lacked effective solutions and are the future of precision medicine in autoimmune and inflammatory diseases.

The 7th Treg-Directed Therapies Summit is your premier event dedicated to exploring and overcoming the unique challenges and advancements specific to Treg. Offering you exclusive access to the latest industry insights, clinical data, Treg biology breakthroughs and strategies for advancing therapies to the clinic from trailblazing companies and academic leaders, including Abata Therapeutics, Harvard Medical School, Nektar Therapeutics, Parvus Therapeutics, PolTreg, ThyTech and many more!
Whether you are in discovery, navigating the complexities of IND filings, or transitioning to the clinic, this forum provides an unparalleled opportunity to engage with leaders at the forefront of cell therapy and modulator innovation. Connect with senior experts in cell therapy manufacturing and modulator production, build strategic relationships with investors, pharmaceutical companies and academics, opening doors to future collaborations and partnership opportunities.
Event guide link: https://ter.li/adqtg1

2nd DNA Process Development & Manufacturing Summit
2025-03-26 - 2025-03-27 | The Hyatt Regency, 1 Ave de Lafayette, Boston, MA, 02111, United States
The 2nd DNA Process Development & Manufacturing Summit: Accelerating Innovative Advanced Therapies with Revolutionary Plasmid & Enzymatic DNA.
With the plasmid DNA manufacturing market set to rise to $39.3Bn by 2033, and the demand for advanced therapies continuing to surge as gene therapy reaches new heights and DNA vaccines promise to transform outbreak response, there has never been a more crucial time to revolutionize the production of high-quality DNA as a starting material and API.
The 2nd DNA Process Development & Manufacturing Summit 2025 returns as the world’s only industry-dedicated technical forum focused on optimizing process development for plasmid and cell-free DNA, adhering to regulatory requirements to streamline IND approvals for advanced therapies, and developing scalable, efficient manufacturing solutions.
Industry experts from the likes of Pfizer, Sanofi, Novartis, Beam Therapeutics, Moderna, Merck and Chroma Medicine are uniting to share innovations in plasmid design, advances off-the-shelf lysis equipment and purification techniques, and strategies to support timely, cost-efficient large-scale DNA production.
Find out more: https://ter.li/7k68s7

Nasal Formulation & Delivery Summit
2025-04-01 - 2025-04-03 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use, nasal delivery is opening a new era of more efficient drug and vaccine administration with life-saving potential. However, challenges in biologics formulation, along with renewed interest from major pharmaceutical companies and investors, raise questions about how other companies are addressing development obstacles and the most effective strategies to secure funding.
Dedicated to navigating investment pathways for nasal companies, boosting drug bioavailability in target regions, optimizing translational modelling, and determining the efficacy of delivery devices, the 3rd Nasal Formulation & Delivery Summit will unite biotechs and innovative start-ups to share case studies and best practices in optimizing nasal drug delivery across different therapeutic areas.
Download the event guide for full details: https://ter.li/qd1z5z
Early bird savings and group discounts up to 20% are available, check out the options here: https://ter.li/u7ehtp

2nd Peptide-Based Therapeutics Summit
2025-04-01 - 2025-04-03 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The 2nd Peptide-Based Therapeutics Summit will return to Boston in April 2025, bringing together over 80 experts in peptide computational science, medicinal chemistry, and formulation to discuss the latest advancements shaping the next generation of peptide-based therapies—from early-stage discovery to clinical application.
Download the three-day program here: https://ter.li/rrvg1v
This year’s summit will highlight groundbreaking innovations in peptide therapeutics, including:

Peptide 3D structure prediction, hit generation, and lead optimization, featuring insights from Chugai Pharmaceutical, PeptiDream, and Insamo
Strategies for optimizing oral bioavailability and cell permeability in peptide design, with contributions from Orbis Medicines and Ohio State University
Peptide formulation techniques for optimal target binding, solubility, stability, and safety, with expertise from Halozyme and Oramed Pharmaceuticals

Join us to shape your peptide drug discovery and development strategy for 2025 and discover the therapeutic potential of cutting-edge peptide-based medicines.

6th TCR-Based Therapies Summit
2025-04-01 - 2025-04-03 | The Revere Hotel Boston Common, 200 Stuart St, Boston, MA, 02116, United States
Returning as the only event created selectively for and by the TCR community, the 6th TCR-based Therapies Summit (April 1-3, 2025 | Boston, MA) is your unique opportunity to connect and collaborate with TCR developers and experts to battle the specific discovery, preclinical and clinical challenges created by T cell receptor biology to advance cell- and bispecific approaches.
View the 25+ experts speaking in 2025 including Adaptimmune, Immunocore, Immatics, BioNTech, T-Knife, TScan, and Affini-T Therapeutics.
View the full lineup of presenting companies in the 2025 Event Guide.
Returning as a much-loved forum by industry leaders in this close-knit community, I’m sure you want to know what’s new for the 2025 meeting:

Plethora of new data: Over 60% of talks will share new data, including clinical insights and advances, novel target case studies, and innovations utilizing AI, machine learning, engineering methods, and cell tracking
Breadth of TCR Approaches: Uncover the realm of TCR targeting methods including TCR-Ts, TCR-NKs, bispecifics, T-cell engagers, TCR-like antibodies, and mimics, and distinguishing the optimal approach for different indications
7 New Companies & 85% New Speakers: Unlock innovations from companies such as Moonlight Bio, Synteny, Alkemist Bio, Pan Cancer T, and Aethon Therapeutics making their TCR-Based Therapies Summit debut and hear new perspectives from a highly refreshed speaker faculty
Applications Beyond Oncology: Discover how TCR therapies can be utilized to treat novel indications, such as autoimmunity and infectious diseases, and harness cross-learnings to propel your therapeutic development

View the full program.
Following Adaptimmune’s milestone approval, the 2025 meeting is anticipated to be one of the best yet. With so much to celebrate, momentum to capture, novel insights, and collaboration with like-minded experts at the only TCR-specific event.
Quick links: Website | Event Guide | Register

15th World Clinical Biomarkers & Companion Diagnostics Summit Europe
2025-04-08 - 2025-04-10 | London, United Kingdom
As recent advances in small molecules, ADCs, cell, and gene therapies poise novel precision therapies from the bench to the clinic, the 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the industry-leading end-to-end forum for Europe’s precision medicine community.
Over three days, 170+ key stakeholders from across Europe working in Biomarkers, Translational Medicine, Precision Medicine, and Companion Diagnostics will come together to:

Bolster biomarker discovery and validation
Implement novel technologies and trials
Pioneer digital and AI-enabled innovations
Optimise drug-diagnostic co-development
Streamline CDx development and commercialisation
Navigate IVDR-adherence

When? 8th-10th April, 2025
Where? London, UK
See the brochure: https://ter.li/exx85v
With free* tickets available for biopharma, check our T&Cs, or view our early bird savings and group discounts: https://ter.li/5uhfl8

Tumour Models Summit Nordics
2025-04-09 - 2025-04-10 | Hilton Stockholm Slussen, Guldgränd 8, Stockholm, 104 65, Sweden
Welcome to the first ever Tumour Models Summit Nordics. This April, the critically acclaimed Tumour Models series will be coming to the Nordics for the first time ever, uniting more than seventy pharma, biotech, and research leaders across the Nordic biotech landscape.
The inherent heterogeneity of cancer – both inter-patient and intra-tumoral – remains a significant challenge in cancer modelling. With only 5% of cancer drugs successfully advancing to clinical trials, there is a critical need for more accurate and predictive models to guide therapeutic development.
To serve this need, the Tumour Models Summit Nordics will unite pharma, biotech, and research leaders from across the thriving Nordic biotech ecosystem to tackle this challenge head-on for the first time ever. Experts working across preclinical, translational, discovery, toxicity, and biology will gather in Stockholm this April to collaborate and overcome the industry’s biggest obstacles for 2025. As the region’s only industry-led event of its kind, this summit provides a rare opportunity to connect with top experts from these developmental areas.
Gain insights into the cutting-edge innovation in in vivo and in vitro tumour modelling, discover strategies to de-risk your studies, and learn how to refine your drug development pipeline.
Key highlights of the agenda include:

Leveraging cutting-edge 3D in vitro models with Roche
Target/receptor axis modelling with Anocca
Humanised mouse models with BioInvent
Advanced omics data with Curacell
Treating solid tumours with Hemispherian

Previous attendees of the Tumour Models Summits in Boston, San Francisco, and London have celebrated the summit’s range, relevance, and focus with comments such as, “This summit included the most cutting-edge achievements and potential collaborations in the scientific and industrial world” (Roche), and “The conference exceeded my expectations. The talks were very relevant to my day-to-day work as in vivo scientist in a cell therapy company. I enjoyed the networking; attendees were very approachable” (Arsenal Biosciences).
Find out why they said this and secure your free pass to join us to engage with decision-makers, explore groundbreaking solutions, and accelerate the path from lab to patient in today’s rapidly evolving landscape.
We’ll see you there!
Get your free pass now whilst still available: https://ter.li/qdc9zo

LEAP HR: Life Sciences West
2025-04-22 - 2025-04-24 | Grand Hyatt San Francisco, 345 Stockton St, San Francisco, CA, 94108, United States
LEAP HR: Life Sciences West is your chance to explore how leading and emerging biopharma organizations are navigating industry volatility and preparing for the workforce of tomorrow. As the sector recovers from funding challenges and workforce reductions, discover innovative ways to align your HR strategy with evolving business needs in 2025 and beyond.
Join 200+ HR leaders to uncover how the most agile organizations are reshaping total rewards strategies to gain a competitive edge in a fiercely competitive talent market. Learn how they’re redefining employee engagement to boost retention and creating flexible workforce planning strategies to adapt to rapid industry changes.
This is your opportunity to rethink HR practices and position your organization for long-term success in Life Sciences.
To know more visit: https://ter.li/fxwk88

4th ADC Analytical Development Summit
2025-04-28 - 2025-04-30 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Unlock the Future of ADC Analytics at the 4th ADC Analytical Development Summit!
When: April 2025
Where: Boston
The 4th ADC Analytical Development Summit is back, bringing together top minds and innovators to tackle the unique analytical challenges of antibody-drug conjugates. With ADCs becoming more complex and regulatory requirements tightening, this event will be your ultimate guide to mastering strategies that ensure high-quality products and seamless regulatory submissions.
View the program here: https://ter.li/hi4hm1

Why You Can’t Miss This Summit:
3 Days of Cutting-Edge Scientific Content
Explore sessions that cover critical topics, including:

Optimizing DAR quantification
Improving aggregation analysis
Refining impurity profiling for advanced ADC development

25+ Expert Speakers
Learn from top industry leaders and innovators, featuring experts from:

AstraZeneca
AbbVie
Sutro Biopharma
Merck
…and many more!

6+ Hours of Interactive Workshops
Participate in hands-on workshops to dive deeper into:

Strategies for accelerated approvals
Advanced profiling techniques for product characterization
Potency optimization for improved therapeutic outcomes
Crafting data packages for smooth regulatory submissions

5+ Hours of High-Impact Networking
Connect with over 120 analytical scientists and quality control specialists to build valuable collaborations and share expertise.
Find out more here: https://ter.li/hi4hm1

2nd Measuring Patient Engagement Summit
2025-04-29 - 2025-05-01 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
As the healthcare industry evolves, patient engagement has become a crucial factor in shaping clinical trials, accelerating regulatory approvals, and improving the overall patient experience.
Yet, amidst a challenging funding environment, empowered patients rightfully demanding greater involvement in treatment decisions, and regulatory bodies requiring transparent reporting of patient engagement activities, it has become more critical than ever to establish quantitative measures for assessing the impact of these initiatives.
The 2nd Annual Measuring Patient Engagement Summit 2025 is the premier event dedicated to addressing this challenge. Bringing together top experts from Patient Engagement, Advocacy, Affairs, Experience, Insights, and Marketing, this summit offers a platform for thought leaders to share data-driven strategies and actionable insights. Attendees will explore innovative case studies that showcase how patient engagement initiatives can be effectively measured, ensuring they deliver real impact while meeting compliance and ROI expectations.
Key topics will include:

Establishing standardized metrics for patient engagement success
Aligning patient engagement strategies with regulatory expectations
Demonstrating ROI to internal and external stakeholders
Leveraging patient insights to improve trial design and healthcare outcomes

By uniting industry leaders to develop a consistent framework for measuring patient engagement, this event ensures that patient-centered innovation remains at the forefront of healthcare transformation.
Join us to drive measurable, meaningful progress in patient engagement — because when we quantify what matters, we create a healthcare system that works for everyone.
To know more visit: www.measuring-patient-engagement-summit.com

2nd GLP-1-Based Therapeutics Summit
2025-04-29 - 2025-05-01 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
The 2nd GLP-1-Based Therapeutics Summit is an exclusive gateway to competitive intelligence into the continued potential of cutting-edge GLP-1s for obesity, weight loss, diabetes, and beyond. Join us to hear the latest clinical data on combination therapies to enhance muscle preservation, indication expansion into new areas, and strategies to improve the efficacy, tolerability, and durability of GLP-1s. With these drugs continuing to dominate the headlines, there is no better time to unite with 100+ C-level executives, decision-makers, and scientists at the forefront of the rapidly evolving world of GLP-1-Based therapeutics.
Learn more: https://ter.li/b0yt9f

3rd mRNA Process Development & Manufacturing Summit Europe
2025-05-06 - 2025-05-08 | Hotel Palace Berlin, Germany
The 3rd mRNA Process Development & Manufacturing Summit 2025 returns as Europe’s premier industry-focused forum, dedicated to optimizing process development for mRNA therapeutics and vaccines. This event will address end-to-end process optimisation, regulatory compliance to streamline approvals, while also advancing scalable and cost-efficient manufacturing solutions, to support drug developers in delivering safer and more effective mRNA drugs to patients faster.
Bringing together leading experts from CEPI, Merck, CureVac, BioNTech, Altamira, Genevation, and more, this summit will showcase cutting-edge advancements in end-to-end process development and manufacturing to support the production of high-quality, cost-effective mRNA therapeutics at scale.
Download the event guide for full details: https://ter.li/4omn9n

2nd ADC Payload Summit
2025-05-06 - 2025-05-08 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The 2nd ADC Payload Summit (May 6-8 | Boston, MA) is the first and only conference exclusively focusing on ADC payloads, helping you to reimagine the medicinal chemistry of traditional cytotoxic payloads while scouting the next generation of ADC payload innovations.

With novel payload categories such as degraders, RNA polymerase II inhibitors, immunomodulators, gene silences, and splice modulators entering the clinic, don’t miss this opportunity to meet with fellow peers to explore the benefits of these diverse mechanisms of action to develop the next blockbuster ADC.
This event will also feature cutting-edge data presentations from emerging players in the field, including Lycia Therapeutics and Heidelberg Pharma, showcasing their latest advancements in payload technologies and clinical trial outcomes. With 80+ professionals from across the ADC landscape in attendance, the summit offers ample networking opportunities to foster collaboration, exchange ideas, and drive the future of ADC therapy forward.
Over three days of deep discussions and collaborative sessions, attendees will gain practical insights into optimizing payload efficacy, improving structure-activity relationships, and exploring the latest payload classes entering the clinic.
Here are some of the agenda highlights you cannot afford to miss:
– Gain insights from Eisai on “Engineering STING/TLR Agonist Payloads to Amplify Anti-Tumor Immune Responses Without Triggering Cytokine Induction” exploring the therapeutic niche and potential of STING agonist payloads.
– Join Takeda in “Navigating the Evolution of ADC Payloads – From Topo1 Success to Future Innovation” to discuss why Topo1 inhibitors dominated the clinic so fast, what other modes of action and payload classes need to do to match that clinical success, and where there is whitespace for novel payloads to gain ground in a competitive ADC landscape.
– Hear from Merck on “Accelerating Degrader-Antibody Conjugate Design Through Strategic Integration of Traditional ADC & Expertise in TPD” to learn about translating physicochemical property optimization strategies from traditional ADCs to address unique degrader payload solubility and stability challenges.
Don’t miss this opportunity to connect with the ADC community and shape the future of payload design. Join us in Boston for this exclusive event and be at the forefront of ADC innovation.
To know more visit: https://ter.li/j0dvm6

4th ALS Drug Development Summit
2025-05-12 - 2025-05-14 | Revere, 200 Stuart St, Boston, MA, 02116, United States
The ALS Drug Development Summit is the definitive industry-led forum dedicated to advancing breakthroughs in ALS therapeutics. With the field evolving rapidly, recent milestones—such as Insitro’s AI-driven target discovery with Bristol Myers Squibb and Dewpoint Therapeutics’ collaboration with Mitsubishi Tanabe Pharma America on TDP-43 condensate modulators—highlight the momentum in novel drug discovery. Meanwhile, QurAlis’ clinical trials for QRL-101 and QRL-201 and innovations in biomarker platforms are reshaping the treatment landscape.
Join 200+ scientific leaders in Boston to tackle key challenges in target validation, biomarker development, and clinical trial optimization—driving progress toward effective ALS and FTD therapies.
To know more visit: https://ter.li/48rlwg

3rd Precision Medicine in Inflammatory Bowel Disease Summit
2025-05-13 - 2025-05-15 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Following a year of exceptional progress in IBD drug development, fierce competition in clinical trials for Chron’s Disease and Ulcerative Colitis remains high, and it’s time for biopharma to push the boundaries of efficacy and distinguish their therapies amongst the market.
Featuring three days of data-driven sessions from 25+ world-class speakers, the 3rd Precision Medicine in Inflammatory Bowel Disease returns as the field’s most comprehensive learning and networking forum; dedicated to showcasing the latest data and advances in IBD therapeutic development.
See the full program here: https://ter.li/tjjok6
With transformative advancements in disease understanding, AI-powered biomarker development, patient stratification, and advanced monitoring techniques paving the way for a new era of precision IBD therapies, join 80+ IBD specialists to:

Refine models and proof-of-concept studies to reduce clinical trial failure rates and improve translational outcomes
Innovate treatment pathways to optimize safety and efficacy
Minimize adverse events while enhancing therapeutic synergies
Leverage emerging therapeutic modalities to refine patient selection and optimize therapeutic outcomes

When & Where: May 13-15, 2025 | Boston, MA
Who: 80+ Precision Medicine, Diagnostics, Translational, Clinical, Computational Biology, Gastrointestinal and Inflammation experts
Agenda: https://ter.li/tjjok6

TPD & Induced Proximity Pharma Partnering Summit
2025-05-19 - 2025-05-20 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
From molecular glue discovery to the development of degrader-antibody conjugates, pharma is transforming through strategic transactions and by leveraging protein degradation technologies to expand target discovery and drug previously ‘undruggable’ targets.
This provides biotech with the opportunity to understand pharma’s targets of interest and the options for increased specificity and selectivity compared to traditional molecules.
Join the TPD & Induced Proximity Pharma Partnering Summit to accelerate partnership interest in your protein degradation pipeline or platform, by hearing first-hand:

What: What are pharma’s targets of interest, and what data is sparking or prohibiting deal-making across TPD?
Who: Who is the right person at each pharma, specifically for induced proximity assets?
How: How are pharma analyzing data for a research collaboration versus a licensing deal?

VIEW THE FULL EVENT GUIDE
Secure your place here or get in touch with the team – info@hansonwade.com

4th GPCRs-Targeted Drug Discovery Summit
2025-05-20 - 2025-05-22 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The 4th GPCR-Targeted Drug Discovery Summit: Transforming the Discovery of Novel GPCR-Targeted Therapies.
With positive clinical read outs by Tectonic Therapeutics and recent funding rounds for Confo Therapeutics & Septerna, the potential for novel GPCR drug classes to treat a plethora of diseases grows. Now more than ever, there is a need for the community to come together to share scientific advancements and collaboration opportunities across the full spectrum of GPCR drugs, from small molecules to therapeutic proteins and antibodies.
The 4th GPCRs-Targeted Drug Discovery Summit is returning to Boston to showcase the hottest targets of interest, mechanism of action of new GPCR ligands, cutting-edge computational tools to identify high-potential candidates, and effective translational strategies to drive forward discovery & development pipelines to patients in need.

Find out everything you need to know about the Summit here: https://ter.li/2c54a7

6th Gene Therapy Analytical Development Summit Europe
2025-05-20 - 2025-05-22 | Novotel London West, 1 Shortlands, Hammersmith, London, W6 8DR, United Kingdom
The 6th Gene Therapy Analytical Development Summit Europe is the leading platform for advancing gene therapy analytics, from IND/IMPD filings to clinical trials and regulatory approvals. As the field moves toward late-stage development, gain industry-focused insights tailored for Europe.
Join 24+ experts to tackle characterisation, stability, contamination risks, and comparability across vectors and diseases. Network with biotech, pharma, MHRA, and British Pharmacopoeia to share solutions and shape the future of gene therapy.
Don’t miss the chance to explore analytical precision, QC strategy, and the delivery of safe, effective therapies!
To know more visit: https://ter.li/w8deua

3rd Retinal Imaging Biomarkers & Endpoints Summit
2025-05-27 - 2025-05-29 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The 3rd Retinal Imaging Biomarkers & Endpoints Summit will bring together leading experts spanning medical directors, researchers, clinical, and imaging scientists from more than 30 organizations spearheading ophthalmic development with deep learning systems and sophisticated AI imaging technologies. It’s here they will explore the latest advancements in retinal imaging, biomarkers, and endpoints for ophthalmic drug development.
This highly anticipated meeting will delve into the evolving landscape of retinal diseases, offering in-depth discussions on innovative imaging techniques, biomarker discovery, and the critical role of endpoints in clinical trials. Attendees will have the opportunity to engage with top-tier scientists, researchers, and industry leaders who will be presenting cutting-edge research, techniques, and case studies, providing you with hyper-relevant insights to accelerate your ophthalmic development.
Topics will cover a range of retinal conditions, including dry and wet AMD, GA, GR, and DME, focusing on the identification and validation of biomarkers that are vital for diagnosis, prognosis, and treatment response assessment. This meeting is the perfect bridge for those developing and using novel technologies to ensure the efficacious development of endpoints for regulatory approval.
Attendees will benefit from interactive workshops, panel discussions, and case studies, providing practical insights into the real-world challenges and opportunities in retinal disease research. Plus, with 8+ hours of dedicated networking sessions designed to ensure attendees get to meet everyone in the room, it’s a fantastic opportunity to build valuable connections and strengthen collaboration which will aid in fostering partnerships that will drive the future of retinal imaging and treatment outcomes.
And with sessions being delivered by Alexion, Opus Genetics, Inflammx, Bausch + Lomb, REGENXBIO, and many more you won’t want to miss this!
Whether you’re a researcher, drug developer, clinician or solution provider, the 3rd Retinal Imaging Biomarkers & Endpoints Summit promises to be a pivotal point in the calendar for those involved in the development of therapies for retinal diseases.
Join us to be at the forefront of this rapidly advancing field and contribute to the next wave of innovations in retinal health…
View the event guide for more information: https://ter.li/hcmzr0
Secure your pass: https://ter.li/tq8jmz

2nd Cell & Gene Therapy Pricing & Reimbursement Summit
2025-05-27 - 2025-05-29 | Marriott Washington Capitol Hill, 175 L Street NE, WA, 20002, United States
Current limitations across pricing, coverage, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that.
Returning for its 2nd edition, this unique summit will share real-world case studies of success and setback in ensuring patients can access CGTs to spearhead reform in this thorny landscape.
Industry-led discussions will center on innovative payment models being developed and applied, new stop-loss and reinsurance programs, and how leading companies are ensuring coverage and uptake of their commercialized therapies. You’ll also leave with actionable learnings from recent CMS policy changes, including the Access Model, Medicaid Drug Rebate Program Final Rule, and proposed increases to inpatient CAR-T reimbursement rates.
Join leading biopharma, government agencies, commercial payers, academics, and market access-specialist service providers – to align on the current market access strategy and policy challenges hindering widespread adoption of these ground-breaking therapies, enhance your payer coverage and improve patient access.
To know more visit: https://ter.li/0g5eq9

4th Circular & Self-Amplifying RNA Therapeutics Summit
2025-05-28 - 2025-05-29 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Join the 4th Circular & Self-Amplifying RNA Therapeutics Summit!
Unleashing the Next Generation of RNAs for Widespread Therapeutic Applications
With CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine, the field of next generation RNAs celebrates the potential of circular and self-amplifying RNAs to provide improved stability, durability, longevity and efficacy for treating a wide array of diseases.
This May, the 4th Circular & Self-Amplifying RNA Therapeutics Summit (previously known as ‘Next Generation RNA Therapeutics Summit) is landing back in Boston, as the unique opportunity to unite with leading stakeholders in the next generation RNA field, including the likes of Sail Biomedicines, Merck, Novo Nordisk, Replicate Bioscience and more. This is your one-stop shop to hear the latest approaches and applications of circular and self-amplifying RNA therapeutics and vaccines and gain actionable insights for fast-tracking your RNA programs toward the clinic.
Join 80+ RNA experts navigating through challenges such as RNA design, delivery, purity, and manufacturing to accelerate high-quality and scalable next-generation RNA therapeutics and vaccines towards approval and the patients in need.
To know more visit: https://ter.li/lemzh2

3rd Gene Therapy Potency Assay Summit
2025-05-28 - 2025-05-29 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Accelerating the Route to Commercialization with Robust Potency Assay Development
Following a challenging year in the gene therapy field, the 3rd Gene Therapy Potency Assay Summit returns at a crucial time when drug developers increasingly recognize that a robust potency assay is fundamental to both clinical success and commercial viability. As regulatory expectations continue to evolve, it has never been more important to develop assays that are accurate, reproducible, and aligned with regulatory standards.
While many industry meetings touch on potency in a broad or non-technical manner, this summit stands apart as the only event fully dedicated to the complexities of potency assay development. With an emphasis on deep technical discussions, attendees will gain unparalleled insights into phase-appropriate assay development, methodology advancements, reducing lot-to-lot variability, and meeting evolving regulatory expectations. By bringing together a specialized community of Analytical Development, Quality Control, and Regulatory experts, this meeting offers a unique platform to discuss challenges, share strategies, and explore innovative solutions.
One of the key highlights of this year’s agenda is the session “Navigating Regulatory Requirements for Gene Therapy Potency Assays”, presented by Melody Dai, Vice President, Head of Regulatory Affairs & CMC at Novasenta. This session, taking place at 9:00 AM on Day 1, will provide an in-depth exploration of regulatory strategies for potency assays, covering both early and ongoing regulatory engagement. Attendees will learn how to build effective relationships with regulatory agencies, navigate evolving requirements, and prepare for critical regulatory meetings and submissions. By leveraging insights from experts with hands-on experience in clinical-stage gene therapy products, this session will offer practical guidance that extends beyond theoretical discussions.
With a carefully curated agenda and contributions from industry leaders, the 3rd Gene Therapy Potency Assay Summit provides an essential opportunity to advance potency assay strategies, enhance regulatory preparedness, and accelerate the path to commercialization. Whether you are refining your assay methodologies, tackling regulatory complexities, or preparing for the next phase of development, this event will equip you with the expertise and connections needed to drive success in gene therapy.
Find Out More Now!
